|
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. |
| |
|
Honoraria - AstraZeneca; Genentech/Roche; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb; Erytech Pharma; Genentech/Roche; Novartis |
Research Funding - Genentech/Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Pierre Fabre |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; MSD; Pfizer; Roche |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daewoong Pharmaceutical; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca; Pfizer; Roche/Genentech |
Travel, Accommodations, Expenses - Novartis; Roche/Genentech |
Other Relationship - Roche |
| |
|
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; Merck; Roche Canada |
Research Funding - AstraZeneca; Merck |
| |
|
|
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis |
| |
|
Consulting or Advisory Role - Eisai; Novartis |
Speakers' Bureau - Basilea; Roche |
Research Funding - Basilea; Roche |
| |
|
Consulting or Advisory Role - Genmab (Inst); Roche (Inst) |
Speakers' Bureau - Eisai (Inst) |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Bayer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck; Merck |
| |
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck |
| |
|
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |